What type of study is this?

This is a Human Clinical Trial study.

December 8, 2025BloodOpen Access

Tislelizumab combined with zanubrutinib and high-dose methotrexate in newly diagnosed primary central nervous system DLBCL: A phase 2 study

View Full Paper

Ask AI

Bookmark

Authors

Phase 2 clinical trial shows improved efficacy and safety profile in PCNS-DLBCL, indicating potential for better outcomes.

Overall response rate reached 100% following six cycles of chemotherapy, with a complete response rate of 85.7%.
The TZM regimen was associated with minimal hematological toxicity but notable non-hematological adverse reactions.
Clinical trial conducted on newly diagnosed patients demonstrated a strong potential to enhance progression-free survival and overall survival.
Findings suggest that combining methotrexate with other treatments may improve outcomes for patients with PCNS-DLBCL.

Guoqiang Liu (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase 2 clinical trial shows improved efficacy and safety profile in PCNS-DLBCL, indicating potential for better outcomes.

Overall response rate reached 100% following six cycles of chemotherapy, with a complete response rate of 85.7%.
The TZM regimen was associated with minimal hematological toxicity but notable non-hematological adverse reactions.
Clinical trial conducted on newly diagnosed patients demonstrated a strong potential to enhance progression-free survival and overall survival.
Findings suggest that combining methotrexate with other treatments may improve outcomes for patients with PCNS-DLBCL.

Guoqiang Liu (2025) studied this question.

View Full Paper

Ask AI

Bookmark